Sun Pharma Q2FY19 preview | Sun Pharma Results | IIFL Securities

Sun Pharma is all set to report its quarterly results on Tuesday. Company's US business is likely to see strong growth over recent product launches and stable price erosion. Watch the video to get full details.

Key Takeaways:
Sun Pharma Revenue (Q2FY19E)
Rs.7,633 (Cr.)
+ 14.8%
Expect improvement in US & EM
India revenue to grow 3-4% (YoY)

Sun Pharma EBITDA (Q2FY19E)
Rs.1,660 (Cr.)
+ 20.6%

Sun Pharma EBITDA Margin (Q2FY19E)
22%, + 100 bps
Margin expansion due to operating leverage and lower pricing pressure

Sun Pharma PAT (Q2FY19E)
Rs.1,015 (Cr.)
+ 11.3%

Q2FY19E: Factors to Watch -
* Generic Products: 6-7% price erosion in US business
* Market share in gWelchol, gGlumetza, gNexium
* Volume growth in Ilumya, Kapspargo Sprinkle, Absorica, Levula
* Key Pipeline products Cequea, Xelpros, upcomiing launches from Halol

Check Out Our New Blogs:

For more informative videos and discussion on important topics related to stock/trading:

Timestamps:
00:00 - Intro
00:08 - Sun Pharma Revenue
00:14 - Sun Pharma EBITDA
00:22 - Sun Pharma EBITDA Margin
00:32 - Sun Pharma PAT
00:39 - Factors to Watch
00:48 - Sun Pharma Industries Ltd

#SunPharma